HC Wainwright Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price

Eton Pharmaceuticals (NASDAQ:ETON) had its price target upped by HC Wainwright from $17.00 to $33.00 in a report released on Thursday, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

ETON has been the subject of a number of other research reports. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. B. Riley started coverage on Eton Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $21.00 price objective for the company.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $16.24 on Thursday. The company’s 50-day simple moving average is $12.70 and its two-hundred day simple moving average is $8.12. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $16.62. The company has a market capitalization of $423.05 million, a price-to-earnings ratio of -73.82 and a beta of 1.38.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eton Pharmaceuticals in the 3rd quarter worth $54,000. Jane Street Group LLC purchased a new stake in Eton Pharmaceuticals in the third quarter valued at about $90,000. Renaissance Technologies LLC boosted its holdings in Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after acquiring an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of Eton Pharmaceuticals during the second quarter worth about $362,000. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at about $373,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.